

**AMBER PHARM LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

Amber Pharm Ltd Contents

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—6

Amber Pharm Ltd
Balance Sheet
As At 31 December 2023

Registered number: 12370121

		2023		2022	
	Notes	£	£	£	£
FIXED ASSETS					
Intangible Assets	4		941,543		1,082,691
Tangible Assets	5		52,591		61,283
Investments	6		1,966,167		2,916,547
			<u>2,960,301</u>		<u>4,060,521</u>
CURRENT ASSETS					
Stocks	7	167,690		154,514	
Debtors	8	1,704,132		353,270	
Cash at bank and in hand		232,987		272,646	
		<u>2,104,809</u>		<u>780,430</u>	
Creditors: Amounts Falling Due Within One Year	9	(1,421,962)		(1,378,707)	
		<u>2,104,809</u>		<u>780,430</u>	
NET CURRENT ASSETS (LIABILITIES)			<u>682,847</u>		<u>(598,277)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>3,643,148</u>		<u>3,462,244</u>
Creditors: Amounts Falling Due After More Than One Year			<u>(3,017,206)</u>		<u>(2,816,216)</u>
NET ASSETS			<u>625,942</u>		<u>646,028</u>
CAPITAL AND RESERVES					
Called up share capital	11	100		100	
Profit and Loss Account		625,842		645,928	
SHAREHOLDERS' FUNDS			<u>625,942</u>		<u>646,028</u>

Amber Pharm Ltd
Balance Sheet (continued)
As At 31 December 2023

For the year ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mr Hiren Patel

Director

Mr Nicky Patel

Director

Mr Baldev Bange

Director

25/11/2024

The notes on pages 3 to 6 form part of these financial statements.

Amber Pharm Ltd
Notes to the Financial Statements
For The Year Ended 31 December 2023

1. General Information

Amber Pharm Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12370121. The registered office is St James House, 65 Mere Green Road, Sutton Coldfield, West Midlands, B75 5BY.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.3. Intangible Fixed Assets and Amortisation - Goodwill

Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the separable net assets. It is amortised to profit and loss account over its estimated economic life of 10 years.

2.4. Intangible Fixed Assets and Amortisation - Other Intangible

Other intangible assets are measured at cost less accumulated amortisation. They are amortised to profit and loss account over their estimated economic life of 5 years.

2.5. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Motor Vehicles	10% reducing balance
Fixtures & Fittings	20% straight line
Computer Equipment	25% straight line

2.6. Leasing and Hire Purchase Contracts

Assets obtained under finance leases are capitalised as tangible fixed assets. Assets acquired under finance leases are depreciated over the shorter of the lease term and their useful lives. Assets acquired under hire purchase contracts are depreciated over their useful lives. Finance leases are those where substantially all of the benefits and risks of ownership are assumed by the company. Obligations under such agreements are included in the creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce a constant periodic rate of charge on the net obligation outstanding in each period.

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to profit and loss account as incurred.

2.7. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

Amber Pharm Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2023

2.8. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 23 (2022: 21)

4. Intangible Assets

	Goodwill	Other	Total
	£	£	£
Cost			
As at 1 January 2023	1,405,000	3,238	1,408,238
As at 31 December 2023	1,405,000	3,238	1,408,238
Amortisation			
As at 1 January 2023	325,161	386	325,547
Provided during the period	140,500	648	141,148
As at 31 December 2023	465,661	1,034	466,695
Net Book Value			
As at 31 December 2023	939,339	2,204	941,543
As at 1 January 2023	1,079,839	2,852	1,082,691

5. Tangible Assets

	Motor Vehicles	Fixtures & Fittings	Computer Equipment	Total
	£	£	£	£
Cost				
As at 1 January 2023	57,023	2,857	15,679	75,559
Additions	-	-	2,008	2,008
As at 31 December 2023	57,023	2,857	17,687	77,567

...CONTINUED

Amber Pharm Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2023

Depreciation

As at 1 January 2023	6,538	499	7,239	14,276
Provided during the period	5,752	572	4,376	10,700
As at 31 December 2023	12,290	1,071	11,615	24,976

Net Book Value

As at 31 December 2023	44,733	1,786	6,072	52,591
As at 1 January 2023	50,485	2,358	8,440	61,283

6. Investments

Subsidiaries
£

Cost

As at 1 January 2023	2,916,547
Additions	520,771
As at 31 December 2023	3,437,318

Provision

As at 1 January 2023	-
Added in period	1,471,151
As at 31 December 2023	1,471,151

Net Book Value

As at 31 December 2023	1,966,167
As at 1 January 2023	2,916,547

7. Stocks

	2023	2022
	£	£
Materials	167,690	154,514

8. Debtors

	2023	2022
	£	£
Due within one year		
Trade debtors	228,451	257,409
Other debtors	80,285	42,861
Amounts owed by subsidiaries	-	50,000
Amounts owed by associates	1,395,396	3,000
	1,704,132	353,270

Amber Pharm Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2023

9. Creditors: Amounts Falling Due Within One Year

	2023	2022
	£	£
Net obligations under finance lease and hire purchase contracts	10,761	10,761
Trade creditors	447,977	380,554
Bank loans and overdrafts	205,000	355,605
Other taxes and social security	117,537	218,251
Other creditors	210,238	121,347
Amounts owed to subsidiaries	15,556	36,008
Amounts owed to associates	414,893	256,181
	<u>1,421,962</u>	<u>1,378,707</u>

10. Obligations Under Finance Leases and Hire Purchase

	2023	2022
	£	£
The future minimum finance lease payments are as follows:		
Not later than one year	10,761	10,761
Later than one year and not later than five years	18,137	25,751
	<u>28,898</u>	<u>36,512</u>
	<u>28,898</u>	<u>36,512</u>

11. Share Capital

	2023	2022
	£	£
Allotted, Called up and fully paid	<u>100</u>	<u>100</u>

12. Related Party Transactions

The company owes £265,893 to NH Pharm Ltd. Nicky Patel and Hiren Patel are directors of this company.

The company owes £96,900 to Baldev Bange a director and shareholder of this company.

The company owes £15,556 to its subsidiary Eccleshall Pharmacy Ltd.

The company is owed £3,300 by InPharm Solutions Ltd, a company which shares the same directors.

The company owes £149,000 to ZSA Traders Ltd. Hiren Patel is a director of this company.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.